Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 6;9(11):1631.
doi: 10.3390/biomedicines9111631.

Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies

Sara Small  1   2 , Yazan Numan  1   2 , Leonidas C Platanias  1   2   3
Affiliations
Review

Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies

Sara Small et al. Biomedicines. .

Abstract

Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being studied to rejuvenate, redirect, or re-enforce the immune system in order to fight off myeloid malignancies. So far, the most successful strategies include interferon treatment and antibody-based therapies, though chimeric antigen receptor (CAR) cells and immune checkpoint inhibitors are also promising therapies. In this review, we discuss the inherent immune mechanisms of defense against myeloid malignancies, currently-approved agents, and agents under investigation. Overall, we evaluate the efficacy and potential of immuno-oncology in the treatment of myeloid malignancies.

Keywords: AML; CAR-T; antibodies; immunotherapy; interferon; myeloid malignancies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. DeMaria O., Cornen S., Daëron M., Morel Y., Medzhitov R., Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574:45–56. doi: 10.1038/s41586-019-1593-5. - DOI - PubMed
    1. Esfahani K., Roudaia L., Buhlaiga N., Del Rincon S., Papneja N., Miller W. A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future. Curr. Oncol. 2020;27:87–97. doi: 10.3747/co.27.5223. - DOI - PMC - PubMed
    1. Marshall H.T., Djamgoz M.B.A. Immuno-Oncology: Emerging Targets and Combination Therapies. Front. Oncol. 2018;8:315. doi: 10.3389/fonc.2018.00315. - DOI - PMC - PubMed
    1. Zhang X., Wang S., Zhu Y., Zhang M., Zhao Y., Yan Z., Wang Q., Li X. Double-edged effects of interferons on the regulation of cancer-immunity cycle. OncoImmunology. 2021;10:1929005. doi: 10.1080/2162402X.2021.1929005. - DOI - PMC - PubMed
    1. Miliotou A., Papadopoulou L. CAR T-cell Therapy: A New Era in Cancer Immunotherapy. Curr. Pharm. Biotechnol. 2018;19:5–18. doi: 10.2174/1389201019666180418095526. - DOI - PubMed

LinkOut - more resources